We Are Continuing To See Strong Growth In Sales, Says Navidea CFO
- Navidea CFO Brent Larson is optimistic regarding the outcomes of the company's upcoming PDUFA dates.
- Sales of Navidea's lead product Lymphoseek in the U.S. are increasing robustly.
- Navidea has no current plans to access the equity capital markets.
- These are only a few key points from this exclusive interview with Mr. Brent Larson.